Entelon Tab.
ApprovedSmall molecule
Entelon Tab. is one of 19 small molecule programs targeting Non-Proliferative Diabetic Retinopathy. It is currently in Approved.
1
Indications
2
Total Trials
0
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
25 competitors in Non-Proliferative Diabetic Retinopathy
#DrugCompanyPhaseTrials
1Lucentis
RocheApproved
Eylea
RegeneronApproved
Luye Pharma Conbercept
CChengdu Kanghong Biotech Co., Ltd.
Approved
Calcium Dobesilate
GGuizhou Bailing Group Pharmaceutical Co Ltd
Approved
Octreotide Depot
NovartisPhase 3
Decadron
QQuince Therapeutics S.p.A.
Phase 3
Vabysmo
RochePhase 2
Glucophage
EMD SeronoPhase 2
KSI-301
KKodiak Sciences Inc
Phase 3
Avastin
BBio-Thera Solutions
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Entelon Tab.. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- HHanlim Pharm. Co., Ltd.